Friday 9 May 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Singapore To Review Its Patent And Copyright Laws

Singapore To Review Its Patent And Copyright Laws

21 May 1995

Singapore will review its patent and copyright laws to comply with new regulations under the international agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), a government minister has said.

The Minister for Trade and Industry, Yeo Cheow Tong, said earlier this month that an inter-ministerial committee has been set up to "examine the TRIPS agreement and review what Singapore needs to do to conform to its obligations under TRIPS."

Mr Yeo made the comments to journalists after performing the ground-breaking ceremony of a new S$300 million ($215.8 million) plant of the US pharmaceutical company Schering-Plough. "As part of the completion of the TRIPS agreement, there are several new requirements with which we have to comply," he said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

Forever Labs spins out SuperShot and appoints new chief executive
Biotechnology
Forever Labs spins out SuperShot and appoints new chief executive
8 May 2025
Pharmaceutical
Gates Foundation pledges $200 billion and sets 2045 sunset in historic shift
8 May 2025
Biotechnology
Crohn’s disease fourth EC approval for Tremfya
8 May 2025
Pharmaceutical
EMA-PRAC measures to minimize risk of suicidal thoughts with finasteride and dutasteride
8 May 2025
Biotechnology
EC approval for BeiGene’s Tevimbra in ES-SCLC
8 May 2025
Biotechnology
PAQ puts $39 million into pot for KRAS degraders
8 May 2025
Pharmaceutical
Takeda reports flat profit as Vyvanse generics take toll
8 May 2025

Company Spotlight

A T-cell immunotherapy company leveraging its novel allogeneic EBV T-cell platform to develop therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.






The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze